Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab as adjuvant therapy in high‑risk locally advanced squamous cell carcinoma of the head and neck
jRCT2080224001Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Tecentriq arm with Placebo arm (2 arms). Primary endpoint: INV-EFS. Started Aug 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2080224001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224001.